bevacizumab

Type: Keyphrase
Name: bevacizumab
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

ReferencesHuebner G, Link H, Kohne CH, et al: Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44-49.Hainsworth ... [Published Sexual Development - 21 hours ago]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Reports from Hospital Clinic Provide New Insights into Cancer Research (First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with...

Reports from Hospital Clinic Provide New Insights into Cancer Research (First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study)By a News Reporter-Staff News Editor at Cancer Weekly Research findings ... [Published Pharmacy Choice - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

FDA Approves Avastin for Advanced Cervical Cancer

The US Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of patients with recurrent or metastatic cervical cancer. The drug is to be used in combination with paclitaxel and either cisplatin or topotecan.“Avastin is the ... [Published Cancernetwork.com - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Roche’s Avastin plus chemotherapy gets FDA approval for cervical cancer treatment

Roche has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan to treat women with persistent, recurrent or metastatic carcinoma of the cer ... [Published PBR - News - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

Cetuximab delivers better overall survival than bevacizumab in metastatic colorectal cancer

Relevant TopicsGastroenterologyLatest News Clinical Trials Research Drugs Reports CorporateDiseases affecting the gastrointestinal tract, which includes the organs from mouth to anus, along the alimentary canal, are the focus of this specialty. Physicians ... [Published BioPortfolio - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Prescription drug wholesaler pleads guilty to smuggling counterfeit cancer drugs

The FDA recently reported that the owner of a Turkish drug wholesaler has pleaded guilty to charges of smuggling misbranded and adulterated cancer treatment drugs into the United States.Sabahaddin Akman, owner of the Turkish firm Ozay Pharmaceuticals, ... [Published Orthopedics Today - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 16 2014 - 2 reports

Cervical Cancer Drug Approved by FDA

Avastin, the new drug developed for the treatment of several types of cancer  has finally been approved for the treatment of cervical cancer in combination with chemotherapy by the Food and Drug Administration. Avastin (containing bevacizumab, monoclonal ... [Published The Utah People's Post - Aug 16 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 13 reports

Avastin Approved for LateStage Cervical Cancer

FRIDAY, Aug. 15, 2014 -- The anti-cancer drug Avastin (bevacizumab) has been newly approved to treat aggressive and late-stage cervical cancer, the U.S. Food and Drug Administration said in a news release.Cervical cancer is most often caused by the.. ... [Published BioPortfolio - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Tackling the Heterogeneity of Triple-Negative Breast Cancer

Figures:Mohammad Jahanzeb, MDWe now accept the heterogeneity of [triple-negative breast cancer], and it’s natural that we think of these groups differently in terms of treatment.—Mohammad Jahanzeb, MDTriple-negative breast cancer is now recognized as ... [Published The ASCO Post - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Lower Risk of Very High Myopia With Bevacizumab for ROP

Reuters Health InformationBy Will Boggs MDAugust 14, 2014NEW YORK (Reuters Health) - Very high myopia is less likely when retinopathy of prematurity (ROP) is treated with bevacizumab instead of conventional lasers, according to results from the BEAT-ROP ... [Published Diabetes Care - Aug 14 2014]
Entities: bevacizumab, Laser, Myopia
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

No difference in response rate but overall survival benefit with firstline FOLFIRIcetuximab versus FOLFIRIbevacizumab in metastic colocrectal cancer

There was no difference in response rate for FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab.In a European phase III FIRE-3 trial reported in The Lancet Oncology, Heinemann et al found no difference in response rate, the primary endpoint, betwee.. ... [Published BioPortfolio - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Medicines update (15)

Questions raised over Digoxin safetyThe long-used atrial fibrillation treatment, Digoxin, may be linked with increased risk of death in patients with newly diagnosed AF, US researchers say.As reported in the Journal of the American College of Cardiology ... [Published Pharmacy News - Aug 13 2014]

Quotes

...to help them live longer than with chemotherapy alone," said Sandra Horning, M D , chief medical officer and head of Global Product Development. "Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, and until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread."
...According to news reporting originating in Barcelona, Spain, by NewsRx journalists, research stated, "Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecitabine in elderly patients with mCRC."
"Until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread."
NEXT ARTICLE More From BioPortfolio on "Roche’s Avastin plus chemotherapy gets FDA approval for cervical cancer treatment"

More Content

All (312) | News (255) | Reports (0) | Blogs (51) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Genentech: Avastin Plus Chemotherapy Secures FD... [Published Individual.com - 8 hours ago]
Carcinoma of Unknown Primary Site Treated with ... [Published Sexual Development - 21 hours ago]
Reports from Hospital Clinic Provide New Insigh... [Published Pharmacy Choice - Aug 19 2014]
Drug for Treatment of Platinum Resistant Recurr... [Published Biotech Daily - Aug 19 2014]
FDA Approves Avastin for Advanced Cervical Cancer [Published Cancernetwork.com - Aug 19 2014]
Roche's Avastin Approved by FDA for Advanced Ce... [Published Yahoo! Finance - Aug 18 2014]
Roche’s Avastin plus chemotherapy receives FDA ... [Published Pharmaceutical Technology - Aug 18 2014]
Cetuximab delivers better overall survival than... [Published BioPortfolio - Aug 18 2014]
Cetuximab delivers better overall survival than... [Published Ecancer Medicalscience - Aug 18 2014]
Amgen’s Executive Medical Director, Richard Mar... [Published Terrapinn - Aug 18 2014]
Roches Avastin plus chemotherapy gets FDA appro... [Published BioPortfolio - Aug 18 2014]
Prescription drug wholesaler pleads guilty to s... [Published Orthopedics Today - Aug 18 2014]
Roche’s Avastin plus chemotherapy gets FDA appr... [Published PBR - News - Aug 18 2014]
Cervical Cancer Biologic Agent Fights Multiple ... [Published The Guardian Express - Aug 17 2014]
Turkish company guilty of smuggling fake Avasti... [Published Examiner.com - Aug 17 2014]
Cervical Cancer Drug Approved by FDA [Published The Utah People's Post - Aug 16 2014]
Avastin proves effective in treating late-stag... [Published Examiner.com - Aug 16 2014]
FDA approves Avastin to treat aggressive and la... [Published Center Watch - Aug 16 2014]
Women and Cancer [Published Clinical Lab Products - Aug 16 2014]
Avastin (Bevacizumab) Plus Chemotherapy Gets FD... [Published PT Community - Aug 15 2014]
Avastin Approved for LateStage Cervical Cancer [Published BioPortfolio - Aug 15 2014]
Avastin Gains New Indication for Metastatic Cer... [Published Chemotherapy Advisor - Aug 15 2014]
New Indication for Avastin Approved [Published Pharmacy Practice News - Aug 15 2014]
Avastin Wins FDA OK for Cervical Cancer [Published MedPageToday.com - medical news plus CME for ph ... - Aug 15 2014]
Avastin Wins FDA Nod for Advanced Forms of Cerv... [Published Genetic Engineering News - Aug 15 2014]
FDA Approves Biologic Agent for Late-Stage Cerv... [Published Pharmacy Times - Aug 15 2014]
Avastin Approved for Late-Stage Cervical Cancer [Published US News & World Report - Aug 15 2014]
Avastin Approved for Late-Stage Cervical Cancer [Published Health Finder - Aug 15 2014]
FDA approves Avastin for aggressive and latesta... [Published BioPortfolio - Aug 15 2014]
FDA Approves Genentech Medicine for Women with ... [Published Genentech - Aug 15 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Roche’s Avastin plus chemotherapy gets FDA appr... [Published PBR - News - Aug 18 2014]
Roche has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan to treat women with persistent, recurrent or metastatic carcinoma of the cer ...
Avastin Wins FDA OK for Cervical Cancer [Published MedPageToday.com - medical news plus CME for ph ... - Aug 15 2014]
WASHINGTON (MedPage Today) -- The FDA has approved the angiogenesis inhibitor bevacizumab for treatment of advanced cervical cancer in combination with chemotherapy. ...
FDA Approves Genentech’s Avastin Plus Chemother... [Published EON Consumer - Aug 14 2014]
SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel ...
FDA Approves Genentech’s Avastin Plus Chemother... [Published Business Wire Health News - Aug 14 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin ...
Roche’s ovarian cancer treatment Avastin gets E... [Published PBR - News - Aug 07 2014]
Swiss health-care firm Roche has received approval from the European Commission to use Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy to treat women with recurrent ovarian cancer that is ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
PledPharma AB (publ) Interim report first quart... [Published GlobeNewswire: Acquisitions News - Apr 25 2014]
Go-ahead for PledPharma to also include Avastin... [Published GlobeNewswire: Advertising News - Apr 23 2014]
Cortice Announces Enrollment of a Phase 2 Trial... [Published GlobeNewswire: Advertising News - Mar 20 2014]
MDxHealth's PredictMDx for Glioblastoma Identif... [Published GlobeNewswire: Advertising News - Mar 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.